• LAST PRICE
    3.8900
  • TODAY'S CHANGE (%)
    Trending Up0.1200 (3.1830%)
  • Bid / Lots
    3.7100/ 5
  • Ask / Lots
    4.1100/ 5
  • Open / Previous Close
    3.8700 / 3.7700
  • Day Range
    Low 3.8450
    High 4.0450
  • 52 Week Range
    Low 1.4200
    High 11.9700
  • Volume
    377,735
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.77
TimeVolumeALDX
09:32 ET34913.93
09:34 ET4263.98
09:36 ET36793.9002
09:38 ET2313.89
09:39 ET14083.855
09:41 ET5003.88
09:48 ET9993.895
09:50 ET10003.89
09:52 ET1003.89
09:54 ET29793.9
09:56 ET3003.915
09:57 ET56953.93
09:59 ET22183.92
10:14 ET2003.925
10:15 ET5033.93
10:17 ET86773.93
10:24 ET26383.945
10:26 ET12003.94
10:28 ET59673.93
10:32 ET12403.93
10:37 ET10863.9312
10:42 ET7003.94
10:46 ET5593.9435
10:50 ET3803.9403
10:53 ET1003.945
10:55 ET26313.94
10:57 ET2003.94
11:04 ET2003.9301
11:09 ET14983.945
11:11 ET53543.945
11:18 ET5303.945
11:20 ET1993.95
11:22 ET15843.94
11:24 ET10003.94
11:26 ET6953.945
11:31 ET5313.94
11:33 ET2003.94
11:40 ET1003.95
11:56 ET101283.95
11:58 ET35413.95
12:02 ET1313.95
12:03 ET413083.9497
12:05 ET77753.95
12:09 ET109903.995
12:12 ET6403.99
12:16 ET2004
12:18 ET13463.99
12:23 ET1004
12:27 ET1003.99
12:30 ET3953.99
12:32 ET428114.02
12:34 ET14004.005
12:36 ET2004.005
12:38 ET1004.02
12:39 ET5004.005
12:41 ET23504.005
12:43 ET2004.005
12:45 ET3004.01
12:48 ET8084.02
12:50 ET106354
12:52 ET1143.99
12:54 ET2004
12:56 ET1003.99
12:57 ET1003.995
12:59 ET1003.995
01:01 ET7003.995
01:06 ET4273.995
01:12 ET56293.995
01:14 ET11643.9801
01:15 ET14003.9742
01:17 ET1003.975
01:21 ET2043.975
01:24 ET2003.975
01:28 ET26883.99
01:30 ET1003.99
01:33 ET1003.99
01:35 ET3004
01:37 ET1003.99
01:39 ET2003.99
01:42 ET102354.01
01:44 ET4004.01
01:46 ET6064.02
01:48 ET2004.02
01:50 ET2004.03
01:51 ET3004.035
01:53 ET19874.04
01:55 ET1004.04
01:57 ET2004.035
02:00 ET22704.03
02:02 ET9284.03
02:04 ET1004.03
02:06 ET1004.03
02:08 ET2004.03
02:09 ET18444.03
02:11 ET1004.03
02:13 ET1004.025
02:15 ET4004.03
02:18 ET12854.045
02:20 ET1004.045
02:22 ET58494.035
02:24 ET31914.02
02:26 ET13444
02:27 ET2003.99
02:29 ET4283.99
02:31 ET3004
02:33 ET4054
02:36 ET2004
02:38 ET18803.99
02:40 ET2004
02:42 ET1003.99
02:44 ET13284
02:45 ET31763.97
02:47 ET2003.97
02:49 ET2003.97
02:51 ET2003.97
02:54 ET3003.965
02:56 ET1003.95
02:58 ET6943.96
03:00 ET3003.97
03:02 ET5003.985
03:03 ET5193.98
03:07 ET5883.97
03:09 ET1003.96
03:12 ET1003.96
03:16 ET3003.97
03:18 ET3993.965
03:20 ET36853.96
03:21 ET48243.94
03:23 ET27003.94
03:27 ET13653.93
03:30 ET11893.89
03:32 ET8003.89
03:34 ET2003.89
03:36 ET3003.9
03:38 ET4003.9
03:39 ET11343.89
03:41 ET6283.86
03:43 ET20003.88
03:45 ET6003.88
03:48 ET9213.89
03:50 ET28853.9
03:52 ET1003.895
03:54 ET37353.895
03:56 ET17803.89
03:57 ET7983.885
03:59 ET291853.89
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALDX
Aldeyra Therapeutics Inc
229.9M
-7.7x
---
United StatesACRV
Acrivon Therapeutics Inc
233.4M
-2.6x
---
United StatesPYXS
Pyxis Oncology Inc
233.8M
-2.8x
---
United StatesATAI
ATAI Life Sciences NV
234.4M
-5.5x
---
United StatesOMER
Omeros Corp
223.1M
-1.3x
---
United StatesATNM
Actinium Pharmaceuticals Inc
238.0M
-4.6x
---
As of 2024-06-12

Company Information

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Contact Information

Headquarters
131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
Phone
781-761-4904
Fax
302-636-5454

Executives

Independent Chairman of the Board
Richard Douglas
President, Chief Executive Officer, Director
Todd Brady
Senior Vice President - Finance, Interim Chief Financial Officer
Bruce Greenberg
Chief Development Officer
Stephen Machatha
Independent Director
Ben Bronstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$229.9M
Revenue (TTM)
$0.00
Shares Outstanding
59.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-0.51
Book Value
$2.02
P/E Ratio
-7.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.